“Biting The Data Management Bullet At GlaxoSmithKline” – Forbes

Jan 17, 2018

By Thomas H. Davenport and Randy Bean – There comes a time in the life of almost every large organization when it has to admit that it doesn’t have the data environment it needs to succeed. For GlaxoSmithKline’s (GSK) Research and Development (R&D) organization, that time was in early 2015. President of the unit Patrick Vallance and his senior colleagues deliberated on whether their data environment was of sufficient quality and integration to develop new drugs in the desired fashion. They examined not only GSK’s situation, but compared it to other companies who were increasingly competing on the basis of their analytical capabilities.

Boston | New York | San Francisco | Raleigh
© 2020 NewVantage Partners. All rights reserved.